首页> 外文期刊>World Journal of Gastroenterology >Key role of mast cells and their major secretory products in inflammatory bowel disease
【24h】

Key role of mast cells and their major secretory products in inflammatory bowel disease

机译:肥大细胞及其主要分泌产物在炎症性肠病中的关键作用

获取原文
获取原文并翻译 | 示例
           

摘要

Historically, mast cells were known as a key cell type involved in type Ⅰ hypersensitivity. Until last two decades, this cell type was recognized to be widely involved in a number of non-allergic diseases including inflammatory bowel disease (IBD). Markedly increased numbers of mast cells were observed in the mucosa of the ileum and colon of patients with IBD, which was accompanied by great changes of the content in mast cells such as dramatically increased expression of TNFα, IL-16 and substance P. The evidence of mast cell degranulation was found in the wall of intestine from patients with IBD with immunohistochemistry technique. The highly elevated histamine and tryptase levels were detected in mucosa of patients with IBD, strongly suggesting that mast cell degranulation is involved in the pathogenesis of IBD. However, little is known of the actions of histamine, tryptase, chymase and carboxypeptidase in IBD. Over the last decade, heparin has been used to treat IBD in clinical practice. The low molecular weight heparin (LMWH) was effective as adjuvant therapy, and the patients showed good clinical and laboratory response with no serious adverse effects. The roles of PGD2, LTC4, PAF and mast cell cytokines in IBD were also discussed. Recently, a series of experiments with dispersed colon mast cells suggested there should be at least two pathways in man for mast cells to amplify their own activation-degranulation signals in an autocrine or paracrine manner. The hypothesis is that mast cell secretogogues induce mast cell degranulation, release histamine, then stimulate the adjacent mast cells or positively feedback to further stimulate its host mast cells through H_1 receptor. Whereas released tryptase acts similarly to histamine, but activates mast cells through its receptor PAR-2. The connections between current anti-IBD therapies or potential therapies for IBD with mast cells were discussed, implicating further that mast cell is a key cell type that is involved in the pathogenesis of IBD. In conclusion, while pathogenesis of IBD remains unclear, the key role of mast cells in this group of diseases demonstrated in the current review implicates strongly that IBD is a mast cell associated disease. Therefore, close attentions should be paid to the role of mast cells in IBD.
机译:从历史上看,肥大细胞是参与Ⅰ型超敏反应的关键细胞类型。直到最近的二十年,这种细胞类型被广泛参与包括炎症性肠病(IBD)在内的许多非过敏性疾病。在IBD患者的回肠和结肠粘膜中观察到肥大细胞的数量明显增加,这伴随着肥大细胞含量的巨大变化,例如TNFα,IL-16和P物质的表达急剧增加。证据免疫组化技术在IBD患者的肠壁发现肥大细胞脱粒。在IBD患者的粘膜中检测到高度升高的组胺和类胰蛋白酶水平,强烈暗示肥大细胞脱粒参与IBD的发病机理。然而,关于IBD中组胺,类胰蛋白酶,糜酶和羧肽酶的作用知之甚少。在过去的十年中,肝素已在临床实践中用于治疗IBD。低分子量肝素(LMWH)作为辅助治疗有效,患者表现出良好的临床和实验室反应,无严重不良反应。还讨论了PGD2,LTC4,PAF和肥大细胞因子在IBD中的作用。最近,一系列关于结肠肥大细胞分散的实验表明,人体内至少应有两条途径使肥大细胞以自分泌或旁分泌的方式放大其自身的活化脱粒信号。假设是肥大细胞促泌素诱导肥大细胞脱粒,释放组胺,然后刺激邻近的肥大细胞或产生正反馈,以通过H_1受体进一步刺激其宿主肥大细胞。而释放的类胰蛋白酶的作用类似于组胺,但通过其受体PAR-2激活肥大细胞。讨论了目前的抗IBD疗法或IBD与肥大细胞的潜在疗法之间的联系,进一步暗示肥大细胞是参与IBD发病机理的关键细胞类型。总之,尽管IBD的发病机理尚不清楚,但本综述中证实的肥大细胞在这一类疾病中的关键作用强烈暗示IBD是与肥大细胞有关的疾病。因此,应密切注意肥大细胞在IBD中的作用。

著录项

  • 来源
    《World Journal of Gastroenterology》 |2004年第3期|p.309-318|共10页
  • 作者

    Shao-Heng He;

  • 作者单位

    Allergy and Inflammation Research Institute, Medical College, Shantou University 22 Xin-Ling Road, Shantou 515031, Guangdong Province, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 消化系及腹部疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号